ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines

References

• Magrath I. Epidemiology: clues to the pathogenesis of Burkitt lymphoma. Br J Haematol. 2012;156:744–756.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Walewski J, Dohner H, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood. 2014;124:3870–3879.
   PubMed Web of Science ®Google Scholar
• Hong J, Kim SJ, Ahn JS, et al. Treatment outcomes of rituximab plus hyper-CVAD in Korean patients with sporadic Burkitt or Burkitt-like lymphoma: results of a multicenter analysis. Cancer Res Treat. 2014;47:173–181.
   PubMedGoogle Scholar
• Jaffe ES, Pittaluga S. Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification. Hematology Am Soc Hematol Educ Program. 2011;2011:506–514.
   PubMedGoogle Scholar
• Sander S, Calado DP, Srinivasan L, et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell. 2012;22:167–179.
   PubMed Web of Science ®Google Scholar
• Dominguez-Sola D, Dalla-Favera R. Burkitt lymphoma: much more than MYC. Cancer Cell. 2012;22:141–142.
   PubMed Web of Science ®Google Scholar
• Bhatti M, Ippolito T, Mavis C, et al. Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma. Oncotarget. 2018;9:21820–21830.
   PubMedGoogle Scholar
• den Hollander J, Rimpi S, Doherty JR, et al. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood. 2010;116:1498–1505.
   PubMed Web of Science ®Google Scholar
• Mori N, Ishikawa C, Senba M, et al. Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas. Biochem Pharmacol. 2011;81:1106.
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440–446.
   PubMed Web of Science ®Google Scholar
• Yun MR, Choi HM, Kang HN, et al. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma. Oncogene. 2018;37:377–388.
   PubMed Web of Science ®Google Scholar
• Shi Y, Frost P, Hoang B, et al. IL-6-induced enhancement of c-Myc translation in multiple myeloma cells: critical role of cytoplasmic localization of the RNA-binding protein hnRNP A1. J Biol Chem. 2011;286:67–78.
   PubMed Web of Science ®Google Scholar
• Zeng R, Tang Y, Zhou H, et al. STAT3 mediates multidrug resistance of Burkitt lymphoma cells by promoting antioxidant feedback. Biochem Biophys Res Commun. 2017;488:182–188.
   PubMed Web of Science ®Google Scholar
• Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor microenvironment. Semin Immunol. 2014;26:38–47.
   PubMed Web of Science ®Google Scholar
• Eichten A, Su J, Adler AP, et al. Resistance to anti-VEGF therapy mediated by autocrine IL6/STAT3 signaling and overcome by IL6 blockade. Cancer Res. 2016;76:2327–2339.
   PubMed Web of Science ®Google Scholar
• Gougelet A, Mansuy A, Blay JY, et al. Lymphoma and myeloma cell resistance to cytotoxic agents and ionizing radiations is not affected by exposure to anti-IL-6 antibody. PLoS One. 2009;4:e8026.
   PubMed Web of Science ®Google Scholar
• Iliopoulos D, Hirsch HA, Wang G, et al. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci USA. 2011;108:1397–1402.
   PubMed Web of Science ®Google Scholar
• Korkaya H, Kim GI, Davis A, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell. 2012;47:570–584.
   PubMed Web of Science ®Google Scholar
• Yin Y, Yao S, Hu Y, et al. The immune-microenvironment confers chemoresistance of colorectal cancer through macrophage-derived IL6. Clin Cancer Res. 2017;23:7375–7387.
   PubMed Web of Science ®Google Scholar
• Steelman LS, Franklin RA, Abrams SL, et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia. 2011;25:1080–1094.
   PubMed Web of Science ®Google Scholar
• Liu Q, Kaneko S, Yang L, et al. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem. 2004;279:52175–52182.
   PubMed Web of Science ®Google Scholar
• Tang A, Gao K, Chu L, et al. Aurora kinases: novel therapy targets in cancers. Oncotarget. 2017;8:23937–23954.
   PubMedGoogle Scholar
• Katayama H, Sasai K, Kawai H, et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet. 2004;36:55–62.
   PubMed Web of Science ®Google Scholar
• Gully CP, Velazquez-Torres G, Shin JH, et al. Aurora B kinase phosphorylates and instigates degradation of p53. Proc Natl Acad Sci USA. 2012;109:E1513–E1522.
   PubMed Web of Science ®Google Scholar
• Yang H, He L, Kruk P, et al. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer. 2006;119:2304–2312.
   PubMed Web of Science ®Google Scholar
• Xu DR, Huang S, Long ZJ, et al. Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells. J Transl Med. 2011;9:74.
   PubMed Web of Science ®Google Scholar
• Carpinelli P, Ceruti R, Giorgini ML, et al. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther. 2007;6:3158–3168.
   PubMed Web of Science ®Google Scholar
• Shapiro GI, Rodon J, Bedell C, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2014;20:233–245.
   PubMed Web of Science ®Google Scholar
• Serra V, Scaltriti M, Prudkin L, et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 2011;30:2547–2557.
   PubMed Web of Science ®Google Scholar
• Toulany M, Minjgee M, Saki M, et al. ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition. Cancer Biol Ther. 2014;15:317–328.
   PubMed Web of Science ®Google Scholar